HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization

Abstract : Background: Heart failure (HF) is a highly prevalent disorder for which disease mechanisms are incompletely understood. The discovery of disease-associated proteins with causal genetic evidence provides an opportunity to identify new therapeutic targets. Methods: We investigated the observational and causal associations of 90 cardiovascular proteins, which were measured using affinity-based proteomic assays. First, we estimated the associations of 90 cardiovascular proteins with incident heart failure by means of a fixed-effect meta-analysis of four population-based studies, comprising a total of 3,019 participants with 732 HF events. The causal effects of HF-associated proteins were then investigated by Mendelian randomization (MR), using cis -protein quantitative loci genetic instruments identified from genome-wide association studies (GWAS) in over 30,000 individuals. To improve the precision of causal estimates, we implemented an MR model that accounted for linkage disequilibrium between instruments and tested the robustness of causal estimates through a multiverse sensitivity analysis that included up to 120 combinations of instrument selection parameters and MR models per protein. The druggability of candidate proteins was surveyed, and mechanism of action and potential on-target side effects were explored with cross-trait MR analysis. Results: 44/90 proteins were positively associated with risk of incident HF (P < 6.0 x 10-4). Among these, eight proteins had evidence of a causal association with HF that was robust to multiverse sensitivity analysis: higher CSF-1 (macrophage colony-stimulating factor 1), Gal-3 (galectin-3) and KIM-1 (kidney injury molecule 1) were positively associated with risk of HF, whereas higher ADM (adrenomedullin), CHI3L1 (chitinase-3-like protein 1), CTSL1 (cathepsin L1), FGF-23 (fibroblast growth factor 23) and MMP-12 (Matrix metalloproteinase-12) were protective. Therapeutics targeting ADM and Gal-3 are currently under evaluation in clinical trials, and all the remaining proteins were considered druggable, except KIM-1. Conclusions: We identified 44 circulating proteins that were associated with incident HF, of which eight showed evidence of a causal relationship and seven were druggable, including adrenomedullin which represents a particularly promising drug target. Our approach demonstrates a tractable roadmap for the triangulation of population genomic and proteomic data for the prioritization of therapeutic targets for complex human diseases.
Complete list of metadata

Contributor : Erwan Bozec Connect in order to contact the contributor
Submitted on : Friday, March 18, 2022 - 4:40:05 PM
Last modification on : Friday, April 22, 2022 - 11:42:06 AM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-09-19

Please log in to resquest access to the document




Albert Henry, María Gordillo-Marañón, Chris Finan, F Schmidt, João Pedro Ferreira, et al.. Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. Circulation, American Heart Association, 2022, ⟨10.1161/CIRCULATIONAHA.121.056663⟩. ⟨hal-03613727⟩



Record views